Our present findings demonstrate that, besides cTFR/cTFH imbalance, the decreased frequency of cTFH17 cells contributes to lupus pathogenesis, particularly lupus nephritis, and blocking the IL-21/IL-21R pathway may facilitate the development of new clinical therapeutics to restrain pathological humoral immunity in SLE (Figure 5). This evidence concerns the gene IL21 and lupus nephritis.